Norway’s Bestillerforum for new methods has completed its meeting on 16 March 2026, and a preliminary protocol has been published.
Methods discussed (nine total):
- Medicines (seven): mepolizumab (Nucala) for uncontrolled COPD with elevated eosinophils; mirdametinib (Ezmekly) for inoperable plexiform neurofibromas in NF1 (paediatric and adult requests); nirogacestat (Ogsiveo) for progressive desmoid tumours; rilzabrutinib (Wayrilz) for refractory ITP; nivolumab (Opdivo) + AVD for previously untreated stage III–IV classical Hodgkin lymphoma (≥12 years); lanadelumab (Takhzyro) extension to ages 2–11 for hereditary angioedema prophylaxis; tiratrikol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency.
- Medical devices/diagnostics (two): DynamX coronary stent for PCI; Airsonett Air 4 (temperature-controlled laminar airflow) for severe allergic asthma.
Updated assignment: apremilast for oral ulcers associated with Behçet’s disease (ID2019_099).
Cancelled assignments: acalabrutinib (Calquence) + bendamustine + rituximab for untreated mantle cell lymphoma (ID2024_082); AI-based analysis of epileptic seizures (Nelli®) (ID2025_019).
Read more at https://www.nyemetoder.no/aktuelt/160326-bestillerforum/
